Trial document

drksid header

DRKS-ID: DRKS00006785

Trial Description

start of 1:1-Block title

Title

Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in Huntington’s disease (HD): A prospective, randomised, controlled, international, multi-centre study

end of 1:1-Block title

start of 1:1-Block acronym

Trial Acronym

HD-DBS

end of 1:1-Block acronym

start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url

start of 1:1-Block public summary

Brief Summary in Lay Language

The aim of the study is to prove the efficacy and safety of deep brain stimulation in patients with Huntington Disease. At present, there is no effective treatment or cure for HD patients. Therefore several groups looked for alternatives, utilising Deep Brain stimulation, based on the long-lasting successful treatment of other neurodegenerative movement disorders like Parkinson’s disease.
Two groups will be compared. Patients in both groups will be implanted with 2 electrodes in the brain. One group will immediately be stimulated for 12 weeks, in the other group the stimulator will only be switched on after these 12 weeks, to test the effect difference after this time. During the first 12 weeks neither the patients nor the physicians know , in which group the patients are. After this time the allocation will be unblinded and both groups will be followed for further 12 weeks in the study.

end of 1:1-Block public summary

start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The aim of the study is to prove the efficacy and safety of pallidal DBS in HD patients and to show superiority of DBS on motor function in the stimulation group compared to stimulation-off group.

end of 1:1-Block scientific synopsis

start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data

start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content

start of 1:1-Block organizational data

Organizational Data

DRKS-ID: DRKS00006785
Date of Registration in DRKS: 2014/09/24
Date of Registration in Partner Registry or other Primary Registry: 2015/08/28
Investigator Sponsored/Initiated Trial (IST/IIT): yes
Ethics Approval/Approval of the Ethics Committee: Approved
(leading) Ethics Committee No.: MPG-LKP-24, Ethik-Kommission an der Medizinischen Fakultät der Heinrich-Heine-Universität Düsseldorf

end of 1:1-Block organizational data

start of 1:n-Block secondary IDs

Secondary IDs

Primary Registry-ID: NCT02535884 (ClinicalTrials.gov)
EUDAMED-No. (for studies acc. to Medical Devices act): CIV-13-12-011770

end of 1:n-Block secondary IDs

start of 1:N-Block indications

Health Condition or Problem studied

ICD10: G10 - Huntington disease

end of 1:N-Block indications

start of 1:N-Block interventions

Interventions/Observational Groups

Arm 1: Pallidal deep brain stimulation during the whole study (2x12weeks)
Arm 2: No pallidal deep brain stimulation for 12 weeks following 12 weeks with stimulation.

end of 1:N-Block interventions

start of 1:1-Block design

Characteristics

Study Type: Interventional
Study Type Non-Interventional: [---]*
Allocation: Randomized controlled trial
Blinding: Blinded
Who is blinded: patient/subject, investigator/therapist, caregiver
Control: Placebo
Purpose: Treatment
Assignment: Parallel
Phase: N/A
Off-label Drug use: N/A

end of 1:1-Block design

start of 1:1-Block primary endpoint

Primary Outcome

Difference between the groups in the UHDRS (Unified Huntingon's Disease Rating Scale) total motor score (UHDRS-TMS) at 12 weeks postoperatively compared to baseline .

end of 1:1-Block primary endpoint

start of 1:1-Block secondary endpoint

Secondary Outcome

Motor function:
-Difference in the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore (items 14-20)
-Difference in the UHDRS bradykinesia subscore (items 22-25 and 27-29)
-Difference in the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) motor score
-Difference in the Q-Motor "choreomotography” test (Reilmann Battery)
-Difference in the Q-Motor “digitomotography” test (Reilmann Battery)
i.Digitomotography – IOI-variability
ii.Dysdiadochomotography – IOI-variability
iii.Manumotography – GFV
iv.Choreomotography – Orientation-index
v.Pedomotography – IOI-variability
Cognition:
-Difference in the Mattis Dementia Rating Scale (MDRS)
-Difference in the Verbal Fluency Test (formal lexical, categorical, category change)
-Difference in the Symbol Digit Modalities Test (SDMT)
-Difference in STROOP word reading, colour naming and colour of the word naming
Psychiatry / Emotion:
-Difference in the Hospital Anxiety and Depression Scale combined with Snaith Irritability Scale (HADS-SIS)
-Difference in the Problem Behaviours Assessment Short Form (PBA-s)
Quality of Life:
-Difference in the Short Form (36) Health Survey (SF-36)
-Difference in the Clinical Global Impression Scale (CGI)

end of 1:1-Block secondary endpoint

start of 1:n-Block recruitment countries

Countries of Recruitment

DE: Germany
AT: Austria
FR: France

end of 1:n-Block recruitment countries

start of 1:n-Block recruitment locations

Locations of Recruitment

University Medical Center Funktionelle Neurochirurgie und Stereotaxie Neurochirurgische Klinik,, Düsseldorf
University Medical Center Charité, University Medicine Berlin Department of Neurology Campus Virchow Klinikum, Berlin
University Medical Center Klinik für Neurochirurgie Abteilung Stereotaktische und Funktionelle Neurochirurgie , Freiburg im Breisgau
University Medical Center Klinikum Großhadern der Ludwig-Maximilians-Universität München, Neurochirurgischen Klinik, München
Medical Center kbo-Isar-Amper-Klinikum Taufkirchen (Vils) , Taufkirchen
University Medical Center Universitätsklinikum Schleswig-Holstein, Abteilung für Neurologie, Kiel
University Medical Center Universitätsklinik Neurologie INSELSPITAL, Universitätsspital Bern CH-3010 Bern, Bern
Medical Center Neurologiezentrum, Siloah, Aerztehaus, 3073 Gümligen, Gümlingen
University Medical Center Neurologie, Medizinische Universität, Anichstrasse 35, 6020 Innsbruck , Innsbruck
University Medical Center Institut für Neurogenetik und Klinik für Neurologie, Ratzeburger Allee 160 23538 Lübeck, Lübeck
Medical Center CHU Amiens Hôpital nord, Department of neurosurgery and Department of neurology, Amiens
Medical Center Hôpital Roger Salengro, Service de Neurologie et Pathologie du mouvement, Lille

end of 1:n-Block recruitment locations

start of 1:1-Block recruitment

Recruitment

Planned/Actual: Actual
(Anticipated or Actual) Date of First Enrollment: 2015/03/18
Target Sample Size: 50
Monocenter/Multicenter trial: Multicenter trial
National/International: International

end of 1:1-Block recruitment

start of 1:1-Block inclusion criteria

Inclusion Criteria

Gender: Both, male and female
Minimum Age: 18 Years
Maximum Age: no maximum age

end of 1:1-Block inclusion criteria

start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

•Clinically symptomatic and genetically confirmed HD (number of CAG repeats ≥ 36)
•Age ≥18 years
•Moderate stage of the disease (UHDRS motor score ≥ 30)
•Chorea despite best medical treatment (UHDRS chorea subscore ≥ 10)
•Mattis Dementia Rating Scale ≥ 120 (or > 80% of items testable independently from motor impairment)
•Patient has stable medication prior six weeks before inclusion
•Signed informed consent

end of 1:1-Block inclusion criteria add

start of 1:1-Block exclusion criteria

Exclusion Criteria

•Juvenile HD (Westphal variant) or predominant bradykinesia
•Postural instability with UHDRS retropulsion score > 2
•Severe comorbidity compromising operability and/or life expectancy and/or quality of life during the trial duration (e.g. cancer with life expectancy < 6 months, NYHA 3 and 4 rising the anaesthetic risk according to the anaesthesiologist)
•Acute suicidality
•Acute psychosis (symptoms within previous 6 months)
•Participation in any interventional clinical trial within 2 months before baseline
•Cortical atrophy grade 3
•Patients with risk of coagulopathies and/or increased risk of haemorrhage
•Patients with an implanted pacemaker or defibrillator
•Pregnancy
•lactation

end of 1:1-Block exclusion criteria

start of 1:n-Block addresses

Addresses

Primary Sponsor
start of 1:1-Block address primary-sponsor
- Universität Düsseldorf
- Heinrich-Heine-Universität Düsseldorf Universitätsstr. 1
- 40225 Düsseldorf
- Germany
end of 1:1-Block address primary-sponsor

start of 1:1-Block address contact primary-sponsor
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact primary-sponsor
Collaborator, Other Address
start of 1:1-Block address other
- Koordinierungszentrum für Klinische Studien Marburg
- Ms. Carmen Schade Brittinger
- Karl-von-Frisch-Strasse 4
- 35043 Marburg
- Germany
end of 1:1-Block address other

start of 1:1-Block address contact other
- Telephone: 06421 2866509
- Fax: 06421 2866517
- E-mail: carmen.brittinger at kks.uni-marburg.de
- URL: [---]*
end of 1:1-Block address contact other
Collaborator, Other Address
start of 1:1-Block address other
- Koordinierungszentrum für Klinische StudienUniversitätsklinikum Düsseldorf
- Ms. Henrike Kolbe
- Moorenstr. 5
- 40225 Düsseldorf
- Germany
end of 1:1-Block address other

start of 1:1-Block address contact other
- Telephone: 02118119700
- Fax: [---]*
- E-mail: Henrike.Kolbe at med.uni-duesseldorf.de
- URL: [---]*
end of 1:1-Block address contact other
Collaborator, Other Address
start of 1:1-Block address other
- Medtronic GmbH
- Mr. Dr. David Keller
- Earl-Bakken-Platz 1
- 40670 Meerbusch
- Germany
end of 1:1-Block address other

start of 1:1-Block address contact other
- Telephone: + 49 160 93901008
- Fax: [---]*
- E-mail: david.keller at medtronic.com
- URL: [---]*
end of 1:1-Block address contact other
Collaborator, Other Address
start of 1:1-Block address other
- CHDI Foundation
- Ms. Christina Sampaio
end of 1:1-Block address other

start of 1:1-Block address contact other
- Telephone: [---]*
- Fax: [---]*
- E-mail: Cristina.Sampaio at chdifoundation.org
- URL: [---]*
end of 1:1-Block address contact other
Contact for Scientific Queries
start of 1:1-Block address scientific-contact
- Funktionelle Neurochirurgie und StereotaxieNeurochirurgische Klinik,Universitätsklinikum DüsseldorfAmbulanz/Sekr.: +49 211 81 16058
- Mr. Prof Dr. Jan Vesper
- Moorenstr. 5
- D-40225 Düsseldorf
- Germany
end of 1:1-Block address scientific-contact

start of 1:1-Block address contact scientific-contact
- Telephone: +49 211 81 18408
- Fax: +49 211 81 015 18408
- E-mail: jan.vesper at uniklinik-duesseldorf.de
- URL: [---]*
end of 1:1-Block address contact scientific-contact
Contact for Public Queries
start of 1:1-Block address public-contact
- Funktionelle Neurochirurgie und StereotaxieNeurochirurgische Klinik,Universitätsklinikum DüsseldorfAmbulanz/Sekr.: +49 211 81 16058
- Mr. Prof Dr. Jan Vesper
- Moorenstr. 5
- D-40225 Düsseldorf
- Germany
end of 1:1-Block address public-contact

start of 1:1-Block address contact public-contact
- Telephone: +49 211 81 18408
- Fax: +49 211 81 015 18408
- E-mail: jan.vesper at uniklinik-duesseldorf.de
- URL: [---]*
end of 1:1-Block address contact public-contact

end of 1:n-Block addresses

start of 1:n-Block material support

Sources of Monetary or Material Support

Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)
start of 1:1-Block address materialSupport
- Bundesministerium für Bildung und Forschung Dienstsitz Berlin
- Hannoversche Straße 28-30
- 10115 Berlin
- Germany
end of 1:1-Block address materialSupport

start of 1:1-Block address contact materialSupport
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: http://www.bmbf.de
end of 1:1-Block address contact materialSupport
Private sponsorship (foundations, study societies, etc.)
start of 1:1-Block address otherSupport
- CHDI Foundation
- Ms. Christina Sampaio
- 6080 Center Drive Suite
- 100 Los Angeles, California, 90045, United States
- United States
end of 1:1-Block address otherSupport

start of 1:1-Block address contact otherSupport
- Telephone: [---]*
- Fax: [---]*
- E-mail: Cristina.Sampaio at chdifoundation.org
- URL: [---]*
end of 1:1-Block address contact otherSupport

end of 1:n-Block material support

start of 1:1-Block state

Status

Recruitment Status: Recruiting complete, follow-up complete
Reason, if "Recruitment stopped after recruiting started" or "Recruiting withdrawn before recruting started": [---]*
Reason, if Reason for Recruiting Stop "Other": [---]*
Study Closing (LPLV): 2021/12/02
Number of Participants in Germany after Recruiting complete: 31
Total Number of Participants (all Sites worldwide) after Recruiting complete: 48

end of 1:1-Block state

start of 1:n-Block publications

Trial Publications, Results and other Documents

[---]*

end of 1:n-Block publications

* This entry means the parameter is not applicable or has not been set.